Streetbeat News

Regulatory

MAXN

Maxeon Solar Technologies, Ltd. has provided an update regarding the detention of its solar panels by the U.S. Customs and Border Protection (CBP). This development could impact the company's operations and stock performance.

Portfolio Pulse from

November 14, 2024 | 1:45 pm

MBRX

Moleculin Biotech, Inc. has announced an acceleration in the unblinding of data for its Phase 3 MIRACLE trial for R/R Acute Myeloid Leukemia, now expected in H2 2025. The trial involves the drug Annamycin in combination with Cytarabine. The company remains on track to treat the first subject in Q1 2025.

Portfolio Pulse from

November 14, 2024 | 1:30 pm

AKBA

Akebia Therapeutics announced the publication of results from the FO2CUS trial in the American Journal of Kidney Disease. The study evaluated the efficacy and safety of vadadustat, an oral HIF-PH inhibitor, in hemodialysis patients for anemia treatment.

Portfolio Pulse from

November 14, 2024 | 1:15 pm

ANNX

Annexon has reported its third quarter 2024 financial results and provided updates on its portfolio. The company anticipates releasing real-world evidence data for ANX005 in Guillain-Barré Syndrome by the end of 2024 and plans to submit a Biologics License Application in the first half of 2025.

Portfolio Pulse from

November 14, 2024 | 1:15 pm

BEN

Levi & Korsinsky has initiated an investigation into Franklin Resources, Inc. (NYSE:BEN) for potential violations of federal securities laws. This follows a Wells Notice received by Ken Leech, co-CIO of its subsidiary Western Asset Management, from the SEC.

Portfolio Pulse from

November 14, 2024 | 1:15 pm

ENLV

Enlivex Therapeutics Ltd. has dosed the first patient in a Phase I clinical trial for Allocetra, targeting psoriatic arthritis. Initial results show no safety concerns.

Portfolio Pulse from

November 14, 2024 | 1:15 pm

BEN

Bleichmar Fonti & Auld LLP is investigating Franklin Resources, Inc. (NYSE: BEN) for potential violations of federal securities laws. Investors in Franklin Resources are encouraged to seek more information.

Portfolio Pulse from

November 14, 2024 | 1:00 pm

PULM

Halper Sadeh LLC is investigating PULM and ENTO for potential violations of federal securities laws and breaches of fiduciary duties to shareholders.

Portfolio Pulse from

November 14, 2024 | 1:00 pm

HRMY

Levi & Korsinsky has initiated an investigation into Harmony Biosciences Holdings, Inc. for potential violations of federal securities laws, following a report by Scorpion Capital raising concerns about their narcolepsy drug, Wakix.

Portfolio Pulse from

November 14, 2024 | 12:45 pm